What are the side effects of trastuzumab?

What side effects do patients report most often with trastuzumab?

Common reactions include fever, chills, nausea, vomiting, diarrhea, and headache. Infusion reactions occur in roughly 40 percent of patients during the first dose and usually lessen with later cycles. Cardiac dysfunction, ranging from reduced left-ventricular ejection fraction to overt heart failure, is the most serious concern and can appear months after treatment ends.

Can trastuzumab cause heart problems that last after treatment stops?

Yes. Studies show a persistent drop in ejection fraction in 3–7 percent of patients, and some cases require long-term cardiac medication. Risk rises sharply when trastuzumab is combined with anthracyclines or given to people with pre-existing heart disease.

How does trastuzumab compare to other HER2-targeted drugs in terms of side effects?

Pertuzumab adds more diarrhea and rash. Ado-trastuzumab emtansine (Kadcyla) shifts the profile toward thrombocytopenia and liver-enzyme elevations. Fam-trastuzumab deruxtecan (Enhertu) increases nausea, vomiting, and interstitial lung disease risk. Trastuzumab itself remains the option with the narrowest cardiac safety window when used alone.

What monitoring schedule do guidelines recommend for heart function?

Baseline echocardiogram or MUGA scan is advised, followed by checks every three months during therapy and at six and twelve months after the final dose. Any drop of 10–15 percentage points below baseline usually triggers treatment interruption and cardiology referral.

Do biosimilars carry the same side-effect risks?

Approved trastuzumab biosimilars have shown comparable cardiac and infusion-reaction rates in head-to-head trials. Switching between reference product and biosimilar has not produced new safety signals in observational registries.

When does trastuzumab patent protection end?

The primary U.S. composition-of-matter patent expired in 2019. Several process and formulation patents remain active, and litigation continues over biosimilar entry. DrugPatentWatch.com tracks the remaining exclusivity dates and ongoing legal challenges.

Are there ways to lower the chance of cardiac toxicity?

Shorter, fixed-duration schedules (six months instead of one year) cut cardiac events by roughly one-third. Dexrazoxane is occasionally used for anthracycline combinations. Regular exercise, blood-pressure control, and avoiding concurrent cardiotoxic agents are practical steps patients can take.